Evidence map›Paper›PMID 30450405›Full record

ArticleJAAD case reports2018

Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma.

Kristi M Lara, Gino K In, George R Matcuk, Arjun Mehta, James S Hu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Talimogene Laherparepvec in Non-Melanoma Cancers.The Journal of clinical and aesthetic dermatology · 2021
    Review
  5. Article
  6. Review
  7. Current concepts and approaches to merkel cell carcinoma.Archives of dermatological research · 2021
    Review
  8. Article
  9. Non-Melanoma Skin Cancers: Biological and Clinical Features.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kristi M LaraUniversity of Southern California, Los Angeles, California.
Gino K InUniversity of Southern California, Los Angeles, California.
George R MatcukUniversity of Southern California, Los Angeles, California.
Arjun MehtaUniversity of Southern California, Los Angeles, California.
James S HuUniversity of Southern California, Los Angeles, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CR, complete responseCT, computed tomographyFDA, US Food and Drug AdministrationMCC, Merkel cell carcinomaMerkel cell carcinomaPD-1, programmed cell death protein-1PD-L1, programmed death ligand-1pembrolizumabprogrammed cell death-1programmed death ligand-1PR, partial responsetalimogene laherparepvecTVEC, talimogene laherparepvec

Identifiers

PMID30450405
PMCPMC6226586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.